Skip to main content

Full text of "USPTO Patents Application 09848616"

See other formats


PTO/SB/25 (09-04) 
Approved for use through 07/31/2006. OMB 0651-0031 
^ U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 

rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 



DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING 
REJECTION OVER A PENDING "REFERENCE" APPLICATION 



Docket Number (Optional) 

1 700.0 180002/BJD/SJE 



In re Application of: SEBBEL et al. 
Application No.: 09/848,616 
FiIed: May 4, 2001 



For: Molecular Antigen Array 

The owner*, CytOS Biotechnology AG , of 100 percent interest in the instant application hereby disclaims, 

except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond 

the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/050,902 , filed 

on January 1 8, 2002 as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference 
application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner 
hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent 
granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is 
binding upon the grantee, its successors or assigns. 

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would 
extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference 
application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the 
grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application: 
expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed 
in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner 
terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. 



Check either box 1 or 2 below, if appropriate. 

1 . ED For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, 

etc.), the undersigned is empowered to act on behalf of the business/organization. 

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and 
belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so 
made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false 
statements may jeopardize the validity of the application or any patent issued thereon. 

2. (X) The undersigned is an attorney or agent of record. Reg. No. 42,473 




December 21 , 2004 



Signature Date 

Brian J. Del Buono 

Typed or printed name 

(202)371-2600 

Telephone Number 

Terminal disclaimer fee under 37 CFR 1.20(d) is included. 



WARNING: Information on this form may become public. Credit card information should not 
be included on this form. Provide credit card information and authorization on PTO-2038. 



*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). 

Form PTO/SB/96 may be used for making this statement. See M PEP § 324. 

This collection of information is required by 37 CFR 1 .321 . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO 
to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, 
including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on 
the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and 
Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS 
ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2. 



12/E2/8004 KNGUYEN1 00000019 09848516 

01 FC:1814 130.00 QP 




PTO/SB/25 (09-04) 
Approved for use through 07/31/2CD6. OMB 0651-0031 
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 
n Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 



TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING 
REJECTION OVER A PENDING "REFERENCE" APPLICATION 



Docket Number (Optional) 

1 700.0 180002/BJD/SJE 



In re Application of: SEBBEL et al . 
Application No.: 09/848,616 
Filed: May 4, 2001 



For: Molecular Antigen Array 

The owner*, CytOS Biotechnology AG , of 100 percent interest in the instant application hereby disclaims, 

except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond 

the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/050,898 , filed 

on January i a, 7002 as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference 
application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner 
hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent 
granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is 
binding upon the grantee, its successors or assigns. 

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would 
extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference 
application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the 
grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application: 
expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed 
in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner 
terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. 

Check either box 1 or 2 below, if appropriate. 

1 . CH For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, 
etc.), the undersigned is empowered to act on behalf of the business/organization. 

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and 
belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so 
made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false 
statements may jeopardize the validity of the application or any patent issued thereon. 



2 . m The undersigned is an attorney or agent of record. Reg. No. HZ,H» / 3 




Signature 

Brian J. Del Buono 



December 21, 2004 

Date 



Typed or printed name 



(202)371-2600 



Telephone Number 



IXl Terminal disclaimer fee under 37 CFR 1 .20(d) is included. 



WARNING: Information on this form may become public. Credit card information should not 
be included on this form. Provide credit card information and authorization on PTO-2038. 



•Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). 
Form PTO/SB/96 may be used for making this statement. See MPEP § 324. 

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO 
to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, 
including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on 
the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and 
Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS 
ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 



If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.